Metadata supporting the published article: Incorporation of biologic factors for the staging of de novo stage IV breast cancer
Creators: name: He, Zhen-Yu
name: Lian, Chen-Lu
name: Wang, Jun
name: Lei, Jian
name: Hua, Li
name: Zhou, Juan
name: Wu, San-Gang
Publisher: name: figshare
Year: 2020
Subjects: Cancer
Medicine
Cancer Diagnosis
Health Care

description: <i>De novo</i> stage IV breast cancer is a rare disease that is considered to be incurable and accounting for approximately 5% of newly diagnosed breast cancer cases.It is critical to investigate whether the biologic factors based on the 8th AJCC stages could also apply to de novo stage IV disease. In light of this, the authors explored the prognostic value of biological factors for this disease using a population-based cohort from the Surveillance, Epidemiology, and End Results (SEER) program.<br><b>Data access</b>: The datasets supporting the findings of this study were extracted from the population-based SEER database (<b>https://seer.cancer.gov/</b>). The data will be made available to researchers who have obtained permission from the SEER programme. Please contact the corresponding author, Dr. Juan Zhou, email adress: <b>zhoujuan@xmu.edu.cn</b> or the SEER program, <b>https://seer.cancer.gov/seertrack/data/request/</b>, for data access requests.<br><b>Study approval:</b> The study was exempt from approval by the Institutional Review Board of the First Affiliated Hospital of Xiamen University because the SEER program provides de-identified information of patients.<br><b>Study aims and methodology:</b>A primary limitation of the AJCC 8th stages is that it is limited to patients with non-metastatic breast cancer. It is critical to investigate whether the biologic factors based on the 8th AJCC stages could also be applied to breast cancer with <i>de novo</i> stage IV disease. In the present study, the authors used a population-based cohort from the SEER program to investigate the prognostic effect of biologic factors in <i>de novo</i> stage IV breast cancer.Data for female breast cancer diagnosed between 2010 and 2014 were extracted from the population-based SEER database. Patients diagnosed with <i>de novo</i> stage IV breast cancer were included. Patients with <i>de novo</i> stage IV breast cancer were defined as distant metastases known at the time of diagnosis or found during the initial staging workup prior to the first course of treatment. Patients for which there was no pathological diagnosis, T0 stage, no data on T stage, N stage, tumor grade, HER2, ER, and PR status were excluded. Patients with unknown metastatic sites, including bone, brain, liver, and lung, were also excluded. Moreover, patients without chemotherapy in HoR+/HER2+, HoR-/HER2+, and HoR-/HER2- subtypes were also excluded from this study. Data from 8,725 patients were included in the analysis.The following variables of interest were extracted: age at diagnosis, race/ethnicity, histology, T stage, N stage, histological grade, ER status, PR status, HER2 status, radiotherapy, surgical procedures, and chemotherapy. In addition, the patterns of distant metastasis, including bone, brain, liver, lung, and other sites of metastasis, were included. TNM stage was determined based on the AJCC 7th staging system. Please read the related article for more details on the statistical analysis.<br><b>Data supporting the figures and tables in the published article:</b> The datasets are in .<b>xlsx</b> file format.Data supporting figure 2: Figure 2.xlsx contains the MDACC risk scores, the SEER risk scores, the cancer-specific survival (CSS) and the time from the initial diagnosis to death from breast cancer (in months)Data supporting figure 3: Figure 3.xlsx contains the MDACC risk scores, the SEER risk scores, the cancer-specific survival (CSS), and the time from the initial diagnosis to death from breast cancer (in months).Data supporting figure 4: Figure 4.xlsx contains the T-stage, SEER risk scores, the cancer-specific survival (CSS), and the time from the initial diagnosis to death from breast cancer (in months).Data supporting figure 5: Figure 5.xlsx contains the N-stage, SEER risk scores, the cancer-specific survival (CSS), and the time from the initial diagnosis to death from breast cancer (in months).Data supporting figure 6: Figure 6.xlsx contains data on the presence of bone metastasis, brain metastasis, liver metastasis, lung metastasis, the number of metastastic sites, and the presence of other metastastic sites. SEER risk scores, the cancer-specific survival (CSS), and the time from the initial diagnosis to death from breast cancer (in months) are also included.Data supporting figure 7: Figure 7.xlsx contains data on the presence of bone metastasis, brain metastasis, liver metastasis, lung metastasis, the number of metastastic sites, and the presence of other metastastic sites. SEER risk scores, the cancer-specific survival (CSS), and the time from the initial diagnosis to death from breast cancer (in months) are also included.Data supporting table 1: Table 1.xlsx contains the following information for the patients included in the study: T stage, N stage, Age, Race, Histological subtypes, Tumor grade, HER2, ER, PR status, Surgery, Radiotherapy, Chemotherapy, Bone metastasis, Brain metastasis, Liver metastasis, Lung metastasis, the number of metastastic sites, Other metastastic site, MDACC risk score, SEER risk score, CSS and time from the initial diagnosis to death from breast cancer (in months).Data supporting table 2: Table 2.xlsx contains the same data as Table 1.xlsx.Data supporting table 3: Table 3.xlsx contains the same data as Table 1.xlsx.Data supporting table 4: Table 4.xlsx contains the same data as Table 1.xlsx.Data supporting table 5: Table 5.xlsx contains the following information for the patients included in the study: T stage, N stage, Bone metastasis, Brain metastasis, Liver metastasis, Lung metastasis, the number of metastastic sites, other metastastic site, SEER risk score, CSS and time from the initial diagnosis to death from breast cancer (in months).<br>